Increased tau phosphorylation and receptor for advanced glycation endproducts (RAGE) in the brain of mice infected with Leishmania amazonensis

Brain, Behavior, and Immunity

Volumn 43, Issue , 2015, Pages 37-45

  Gasparotto, Juciano ^a   Senger, Mario Roberto ^b   Kunzler, Alice ^a   Degrossoli, Adriana ^b   de Simone, Salvatore Giovanni ^b   Bortolin, Rafael Calixto ^a   Somensi, Nauana ^a   Girardi, Carolina Saibro ^a   de Souza, Celeste da Silva Freitas ^b   Calabrese, Kátia da Silva ^b   Dal Pizzol, Felipe ^c   Moreira, José Claudio Fonseca ^a   Silva, Floriano Paes ^b   Gelain, Daniel Pens ^a  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b INSTITUTO OSWALDO CRUZ   (Brazil)

^c UNIVERSIDADE DO EXTREMO SUL CATARINENSE   (Brazil)

Author keywords

Leishmaniasis; Neurodegeneration; Oxidative stress; RAGE; Tau phosphorylation

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; CATALASE; GAMMA INTERFERON; HYDROGEN PEROXIDE; INTERLEUKIN 1BETA; INTERLEUKIN 6; SUPEROXIDE DISMUTASE; TAU PROTEIN; THIOBARBITURIC ACID REACTIVE SUBSTANCE; THIOL GROUP; TUMOR NECROSIS FACTOR ALPHA; ADVANCED GLYCOSYLATION END-PRODUCT RECEPTOR; CYTOKINE; IMMUNOGLOBULIN RECEPTOR;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; BRAIN TISSUE; CONTROLLED STUDY; DOWN SYNDROME; EXPLORATORY RESEARCH; FEMALE; LEISHMANIASIS; LIPID PEROXIDATION; MOUSE; NEUROMODULATION; NONHUMAN; OXIDATION REDUCTION STATE; OXIDATIVE STRESS; PROTEIN CARBONYLATION; PROTEIN CONTENT; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; UPREGULATION; ANIMAL; BAGG ALBINO MOUSE; BRAIN; LEISHMANIA MEXICANA; METABOLISM; PARASITOLOGY; PHOSPHORYLATION; PHYSIOLOGY;

ANIMALS; BRAIN; CYTOKINES; LEISHMANIA MEXICANA; LEISHMANIASIS; MICE; MICE, INBRED BALB C; OXIDATIVE STRESS; PHOSPHORYLATION; RECEPTORS, IMMUNOLOGIC; TAU PROTEINS; UP-REGULATION;

EID: 84919413546     PISSN: 08891591     EISSN: 10902139     Source Type: Journal    
DOI: 10.1016/j.bbi.2014.06.204     Document Type: Article

References (62)

1. Abreu-Silva A.L., Calabrese K.S., Tedesco R.C., Mortara R.A., Goncalves da Costa S.C. Central nervous system involvement in experimental infection with Leishmania (Leishmania) amazonensis. Am. J. Trop. Med. Hyg. 2003, 68:661-665.
2. Aebi H. Catalase in vitro. Methods Enzymol. 1984, 105:121-126.
3. Alexander J., Bryson K. T helper (h)1/Th2 and Leishmania: paradox rather than paradigm. Immunol. Lett. 2005, 99:17-23.
4. Alvar J., Velez I.D., Bern C., Herrero M., Desjeux P., Cano J., Jannin J., den Boer M. Leishmaniasis worldwide and global estimates of its incidence. PLoS One 2012, 7:e35671.
5. Arancio O., Zhang H.P., Chen X., Lin C., Trinchese F., Puzzo D., Liu S., Hegde A., Yan S.F., Stern A., Luddy J.S., Lue L.F., Walker D.G., Roher A., Buttini M., Mucke L., Li W., Schmidt A.M., Kindy M., Hyslop P.A., Stern D.M., Du Yan S.S. RAGE potentiates Abeta-induced perturbation of neuronal function in transgenic mice. EMBO J. 2004, 23:4096-4105.
6. Arrais-Silva W.W., Pinto E.F., Rossi-Bergmann B., Giorgio S. Hyperbaric oxygen therapy reduces the size of Leishmania amazonensis-induced soft tissue lesions in mice. Acta Trop. 2006, 98:130-136.
7. Baccan G.C., Oliveira F., Sousa A.D., Cerqueira N.A., Costa J.M., Barral-Netto M., Barral A. Hormone levels are associated with clinical markers and cytokine levels in human localized cutaneous leishmaniasis. Brain Behav. Immun. 2011, 25:548-554.
8. Baneth G., Aroch I. Canine leishmaniasis: a diagnostic and clinical challenge. Vet. J. 2008, 175:14-15.
9. Barbieri C.L., Giorgio S., Merjan A.J., Figueiredo E.N. Glycosphingolipid antigens of Leishmania (Leishmania) amazonensis amastigotes identified by use of a monoclonal antibody. Infect. Immun. 1993, 61:2131-2137.
10. Barral A., Pedral-Sampaio D., Grimaldi Junior G., Momen H., McMahon-Pratt D., Ribeiro de Jesus A., Almeida R., Badaro R., Barral-Netto M., Carvalho E.M., et al. Leishmaniasis in Bahia, Brazil: evidence that Leishmania amazonensis produces a wide spectrum of clinical disease. Am. J. Trop. Med. Hyg. 1991, 44:536-546.
11. Barroso E., del Valle J., Porquet D., Vieira Santos A.M., Salvado L., Rodriguez-Rodriguez R., Gutierrez P., Anglada-Huguet M., Alberch J., Camins A., Palomer X., Pallas M., Michalik L., Wahli W., Vazquez-Carrera M. Tau hyperphosphorylation and increased BACE1 and RAGE levels in the cortex of PPARbeta/delta-null mice. Biochim. Biophys. Acta 2013, 1832:1241-1248.
12. Bopp C., Bierhaus A., Hofer S., Bouchon A., Nawroth P.P., Martin E., Weigand M.A. Bench-to-bedside review: the inflammation-perpetuating pattern-recognition receptor RAGE as a therapeutic target in sepsis. Crit. Care 2008, 12:201.
13. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 1976, 72:248-254.
14. Brelaz-de-Castro M.C., de Almeida A.F., de Oliveira A.P., de Assis-Souza M., da Rocha L.F., Pereira V.R. Cellular immune response evaluation of cutaneous leishmaniasis patients cells stimulated with Leishmania (Viannia) braziliensis antigenic fractions before and after clinical cure. Cell. Immunol. 2012, 279:180-186.
15. Candela P., Gosselet F., Saint-Pol J., Sevin E., Boucau M.C., Boulanger E., Cecchelli R., Fenart L. Apical-to-basolateral transport of amyloid-beta peptides through blood-brain barrier cells is mediated by the receptor for advanced glycation end-products and is restricted by P-glycoprotein. J. Alzheimers Dis. 2010, 22:849-859.
16. Coughlan M.T., Cooper M.E., Forbes J.M. Renal microvascular injury in diabetes: RAGE and redox signaling. Antioxid. Redox Signal. 2007, 9:331-342.
17. David C.V., Craft N. Cutaneous and mucocutaneous leishmaniasis. Dermatol. Ther. 2009, 22:491-502.
18. de Bittencourt Pasquali M.A., Gelain D.P., Zeidan-Chulia F., Pires A.S., Gasparotto J., Terra S.R., Moreira J.C. Vitamin A (retinol) downregulates the receptor for advanced glycation endproducts (RAGE) by oxidant-dependent activation of p38 MAPK and NF-kB in human lung cancer A549 cells. Cell. Signal. 2013, 25:939-954.
19. de Moura T.R., Novais F.O., Oliveira F., Clarencio J., Noronha A., Barral A., Brodskyn C., de Oliveira C.I. Toward a novel experimental model of infection to study American cutaneous leishmaniasis caused by Leishmania braziliensis. Infect. Immun. 2005, 73:5827-5834.
20. Desjeux P. Leishmaniasis: current situation and new perspectives. Comp. Immunol. Microbiol. Infect. Dis. 2004, 27:305-318.
21. Draper H.H., Hadley M. Malondialdehyde determination as index of lipid peroxidation. Methods Enzymol. 1990, 186:421-431.
22. Du Yan S., Zhu H., Fu J., Yan S.F., Roher A., Tourtellotte W.W., Rajavashisth T., Chen X., Godman G.C., Stern D., Schmidt A.M. Amyloid-beta peptide-receptor for advanced glycation endproduct interaction elicits neuronal expression of macrophage-colony stimulating factor: a proinflammatory pathway in Alzheimer disease. Proc. Natl. Acad. Sci. U. S. A. 1997, 94:5296-5301.
23. Ellman G.L. Tissue sulfhydryl groups. Arch. Biochem. Biophys. 1959, 82:70-77.
24. Engwerda C.R., Ato M., Kaye P.M. Macrophages, pathology and parasite persistence in experimental visceral leishmaniasis. Trends Parasitol. 2004, 20:524-530.
25. Gendron T.F., Petrucelli L. The role of tau in neurodegeneration. Mol. Neurodegen. 2009, 4:13.
26. Guo Z.J., Niu H.X., Hou F.F., Zhang L., Fu N., Nagai R., Lu X., Chen B.H., Shan Y.X., Tian J.W., Nagaraj R.H., Xie D., Zhang X. Advanced oxidation protein products activate vascular endothelial cells via a RAGE-mediated signaling pathway. Antioxid. Redox Signal. 2008, 10:1699-1712.
27. Halliwell B. Oxidative stress and neurodegeneration: where are we now?. J. Neurochem. 2006, 97:1634-1658.
28. Ibrahim Z.A., Armour C.L., Phipps S., Sukkar M.B. RAGE and TLRs: relatives, friends or neighbours?. Mol. Immunol. 2013, 56:739-744.
29. Kastle M., Grune T. Protein oxidative modification in the aging organism and the role of the ubiquitin proteasomal system. Curr. Pharm. Des. 2011, 17:4007-4022.
30. Kojro E., Postina R. Regulated proteolysis of RAGE and AbetaPP as possible link between type 2 diabetes mellitus and Alzheimer's disease. J. Alzheimers Dis. 2009, 16:865-878.
31. Krstic D., Madhusudan A., Doehner J., Vogel P., Notter T., Imhof C., Manalastas A., Hilfiker M., Pfister S., Schwerdel C., Riether C., Meyer U., Knuesel I. Systemic immune challenges trigger and drive Alzheimer-like neuropathology in mice. J. Neuroinflamm. 2012, 9:151.
32. Leclerc E., Fritz G., Weibel M., Heizmann C.W., Galichet A. S100B and S100A6 differentially modulate cell survival by interacting with distinct RAGE (receptor for advanced glycation end products) immunoglobulin domains. J. Biol. Chem. 2007, 282:31317-31331.
33. Levine R.L., Garland D., Oliver C.N., Amici A., Climent I., Lenz A.G., Ahn B.W., Shaltiel S., Stadtman E.R. Determination of carbonyl content in oxidatively modified proteins. Methods Enzymol. 1990, 186:464-478.
34. Li X.H., Lv B.L., Xie J.Z., Liu J., Zhou X.W., Wang J.Z. AGEs induce Alzheimer-like tau pathology and memory deficit via RAGE-mediated GSK-3 activation. Neurobiol. Aging 2012, 33:1400-1410.
35. Li Y., Liu L., Barger S.W., Griffin W.S. Interleukin-1 mediates pathological effects of microglia on tau phosphorylation and on synaptophysin synthesis in cortical neurons through a p38-MAPK pathway. J. Neurosci. 2003, 23:1605-1611.
36. Lissi E., Pascual C., Del Castillo M.D. Luminol luminescence induced by 2,2'-Azo-bis(2-amidinopropane) thermolysis. Free. Radic. Res. Commun. 1992, 17:299-311.
37. Maczurek A., Shanmugam K., Munch G. Inflammation and the redox-sensitive AGE-RAGE pathway as a therapeutic target in Alzheimer's disease. Ann. N. Y. Acad. Sci. 2008, 1126:147-151.
38. Maioli T.U., Takane E., Arantes R.M., Fietto J.L., Afonso L.C. Immune response induced by New World Leishmania species in C57BL/6 mice. Parasitol. Res. 2004, 94:207-212.
39. Mancini A., Festa R., Di Donna V., Leone E., Littarru G.P., Silvestrini A., Meucci E., Pontecorvi A. Hormones and antioxidant systems: role of pituitary and pituitary-dependent axes. J. Endocrinol. Invest. 2010, 33:422-433.
40. McGwire B.S., Satoskar A.R. Leishmaniasis: clinical syndromes and treatment. QJM 2013, 107:7-14.
41. Melo G.D., Seraguci T.F., Schweigert A., Silva J.E., Grano F.G., Peiro J.R., Lima V.M., Machado G.F. Pro-inflammatory cytokines predominate in the brains of dogs with visceral leishmaniasis: a natural model of neuroinflammation during systemic parasitic infection. Vet. Parasitol. 2013, 192:57-66.
42. Misra H.P., Fridovich I. The role of superoxide anion in the autoxidation of epinephrine and a simple assay for superoxide dismutase. J. Biol. Chem. 1972, 247:3170-3175.
43. Mondragon-Rodriguez S., Perry G., Luna-Munoz J., Acevedo-Aquino M.C., Williams S. Phosphorylation of tau protein at sites Ser(396-404) is one of the earliest events in Alzheimer's disease and Down syndrome. Neuropathol. Appl. Neurobiol. 2014, 40:121-135.
44. Mondragon-Rodriguez S., Perry G., Zhu X., Moreira P.I., Acevedo-Aquino M.C., Williams S. Phosphorylation of tau protein as the link between oxidative stress, mitochondrial dysfunction, and connectivity failure: implications for Alzheimer's disease. Oxid. Med. Cell. Longev. 2013, 2013:940603.
45. Murray H.W., Berman J.D., Davies C.R., Saravia N.G. Advances in leishmaniasis. Lancet 2005, 366:1561-1577.
46. Oliveira F.J., Cecchini R. Oxidative stress of liver in hamsters infected with Leishmania (L.) chagasi. J. Parasitol. 2000, 86:1067-1072.
47. Oliveira W.N., Ribeiro L.E., Schrieffer A., Machado P., Carvalho E.M., Bacellar O. The role of inflammatory and anti-inflammatory cytokines in the pathogenesis of human tegumentary leishmaniasis. Cytokine 2014, 66:127-132.
48. Pereira B.A., Alves C.R. Immunological characteristics of experimental murine infection with Leishmania (Leishmania) amazonensis. Vet. Parasitol. 2008, 158:239-255.
49. Petersen C.A., Greenlee M.H. Neurologic manifestations of Leishmania spp. Infection. J. Neuroparasitol. 2011, 2:10-20.
50. Ramos C.S., Yokoyama-Yasunaka J.K., Guerra-Giraldez C., Price H.P., Mortara R.A., Smith D.F., Uliana S.R. Leishmania amazonensis META2 protein confers protection against heat shock and oxidative stress. Exp. Parasitol. 2011, 127:228-237.
51. Roe A.D., Staup M.A., Serrats J., Sawchenko P.E., Rissman R.A. Lipopolysaccharide-induced tau phosphorylation and kinase activity-modulation, but not mediation, by corticotropin-releasing factor receptors. Eur. J. Neurosci. 2011, 34:448-456.
52. Salminen A., Ojala J., Kauppinen A., Kaarniranta K., Suuronen T. Inflammation in Alzheimer's disease: amyloid-beta oligomers trigger innate immunity defence via pattern recognition receptors. Prog. Neurobiol. 2009, 87:181-194.
53. Schmitt K., Grimm A., Kazmierczak A., Strosznajder J.B., Gotz J., Eckert A. Insights into mitochondrial dysfunction: aging, amyloid-beta, and tau-A deleterious trio. Antioxid. Redox Signal. 2012, 16:1456-1466.
54. Shacter E., Williams J.A., Lim M., Levine R.L. Differential susceptibility of plasma proteins to oxidative modification: examination by western blot immunoassay. Free Radic. Biol. Med. 1994, 17:429-437.
55. Shi J.Q., Shen W., Chen J., Wang B.R., Zhong L.L., Zhu Y.W., Zhu H.Q., Zhang Q.Q., Zhang Y.D., Xu J. Anti-TNF-alpha reduces amyloid plaques and tau phosphorylation and induces CD11c-positive dendritic-like cell in the APP/PS1 transgenic mouse brains. Brain Res. 2011, 1368:239-247.
56. Sims G.P., Rowe D.C., Rietdijk S.T., Herbst R., Coyle A.J. HMGB1 and RAGE in inflammation and cancer. Annu. Rev. Immunol. 2010, 28:367-388.
57. Sonnen J.A., Breitner J.C., Lovell M.A., Markesbery W.R., Quinn J.F., Montine T.J. Free radical-mediated damage to brain in Alzheimer's disease and its transgenic mouse models. Free Radic. Biol. Med. 2008, 45:219-230.
58. Souza V.L., Veras P.S., Welby-Borges M., Silva T.M., Leite B.R., Ferraro R.B., Meyer-Fernandes J.R., Barral A., Costa J.M., de Freitas L.A. Immune and inflammatory responses to Leishmania amazonensis isolated from different clinical forms of human leishmaniasis in CBA mice. Mem. Inst. Oswaldo Cruz 2011, 106:23-31.
59. Spires-Jones T.L., Stoothoff W.H., de Calignon A., Jones P.B., Hyman B.T. Tau pathophysiology in neurodegeneration: a tangled issue. Trends Neurosci. 2009, 32:150-159.
60. Srikanth V., Maczurek A., Phan T., Steele M., Westcott B., Juskiw D., Munch G. Advanced glycation endproducts and their receptor RAGE in Alzheimer's disease. Neurobiol. Aging 2011, 32:763-777.
61. Wang J.Z., Xia Y.Y., Grundke-Iqbal I., Iqbal K. Abnormal hyperphosphorylation of tau: sites, regulation, and molecular mechanism of neurofibrillary degeneration. J. Alzheimers Dis. 2013, 33(Suppl. 1):S123-S139.
62. Yan S.D., Bierhaus A., Nawroth P.P., Stern D.M. RAGE and Alzheimer's disease: a progression factor for amyloid-beta-induced cellular perturbation?. J. Alzheimers Dis. 2009, 16:833-843.